{"id":"n-803","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"N-803 is an engineered IL-15 superagonist complex designed to preferentially stimulate IL-15 receptor signaling on natural killer (NK) cells and CD8+ T lymphocytes while minimizing activation of regulatory T cells. By amplifying these cytotoxic immune populations, N-803 aims to enhance tumor recognition and destruction. It is being developed as an immunotherapy agent to boost endogenous anti-tumor immune responses.","oneSentence":"N-803 is a superagonist of the IL-15 receptor that expands and activates natural killer cells and CD8+ T cells to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:30.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma (in combination with checkpoint inhibitors)"},{"name":"Renal cell carcinoma"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07108036","phase":"PHASE2","title":"A Study to Assess Anktiva in Patients With Long Covid-19.","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11-14","conditions":"Long COVID","enrollment":20},{"nctId":"NCT05642195","phase":"PHASE1, PHASE2","title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT05419011","phase":"PHASE2","title":"Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-08","conditions":"Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome","enrollment":186},{"nctId":"NCT06745908","phase":"PHASE3","title":"ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-10-01","conditions":"NSCLC Stage IV","enrollment":460},{"nctId":"NCT07492888","phase":"PHASE2","title":"Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04-15","conditions":"Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis","enrollment":20},{"nctId":"NCT07488884","phase":"PHASE1","title":"Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-03-01","conditions":"Pancreatic Cancer Resectable, Pancreatic Cancer","enrollment":30},{"nctId":"NCT02138734","phase":"PHASE1, PHASE2","title":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2014-07-21","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":596},{"nctId":"NCT07217496","phase":"PHASE1","title":"N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer","status":"WITHDRAWN","sponsor":"Vadim S Koshkin","startDate":"2026-02-15","conditions":"Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma","enrollment":""},{"nctId":"NCT07477366","phase":"PHASE2","title":"Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04","conditions":"Relapsed B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT07125872","phase":"PHASE2","title":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11-11","conditions":"Relapsed B-Cell Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT06149481","phase":"PHASE1, PHASE2","title":"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-03-26","conditions":"Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT06253494","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-14","conditions":"Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium","enrollment":60},{"nctId":"NCT04290546","phase":"PHASE1","title":"CIML NK Cell in Head & Neck Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-07-20","conditions":"Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT07085338","phase":"PHASE2","title":"A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-11-10","conditions":"Neuroblastoma Recurrent","enrollment":54},{"nctId":"NCT06061809","phase":"PHASE2","title":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2024-08-07","conditions":"Glioblastoma","enrollment":34},{"nctId":"NCT07049432","phase":"PHASE1","title":"N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2026-02","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":13},{"nctId":"NCT07145164","phase":"PHASE2","title":"Interleukin-15 to Promote Post-ART Control of HIV","status":"ENROLLING_BY_INVITATION","sponsor":"Michael Peluso, MD","startDate":"2025-08-19","conditions":"HIV","enrollment":20},{"nctId":"NCT07355205","phase":"PHASE2","title":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent","enrollment":26},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT04847466","phase":"PHASE2","title":"Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-14","conditions":"Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC","enrollment":18},{"nctId":"NCT04390399","phase":"PHASE2","title":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2020-07-21","conditions":"Pancreatic Cancer","enrollment":328},{"nctId":"NCT05245292","phase":"PHASE1","title":"3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rockefeller University","startDate":"2022-12-07","conditions":"Human Immunodeficiency Virus","enrollment":28},{"nctId":"NCT04898543","phase":"PHASE1","title":"QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2021-06-21","conditions":"Metastatic Solid Tumor","enrollment":50},{"nctId":"NCT07261657","phase":"EARLY_PHASE1","title":"N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-09-02","conditions":"Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma","enrollment":8},{"nctId":"NCT07123727","phase":"PHASE2","title":"A Study to Examine Anktiva for the Treatment of COVID-19.","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-09-04","conditions":"Long COVID, Long COVID Syndrome, Long Covid 19","enrollment":40},{"nctId":"NCT06161545","phase":"PHASE2","title":"Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-09-24","conditions":"Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck, Stage IV Squamous Cell Carcinoma of the Head and Neck","enrollment":40},{"nctId":"NCT06710288","phase":"PHASE2","title":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2024-11-06","conditions":"Platinum-resistant Ovarian Cancer","enrollment":20},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT06829823","phase":"PHASE2","title":"Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":20},{"nctId":"NCT03022825","phase":"PHASE2, PHASE3","title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2017-06-02","conditions":"Bladder Cancer","enrollment":190},{"nctId":"NCT05618925","phase":"PHASE1","title":"Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-08-22","conditions":"Non Hodgkin's Lymphoma Refractory/Relapsed","enrollment":20},{"nctId":"NCT06956547","phase":"","title":"Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy","status":"AVAILABLE","sponsor":"ImmunityBio, Inc.","startDate":"","conditions":"Lymphopenia","enrollment":""},{"nctId":"NCT06040918","phase":"PHASE1","title":"Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis","status":"COMPLETED","sponsor":"ImmunityBio, Inc.","startDate":"2023-10-04","conditions":"Healthy Subjects","enrollment":10},{"nctId":"NCT03493945","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-01","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm","enrollment":59},{"nctId":"NCT04247282","phase":"PHASE1, PHASE2","title":"Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-09","conditions":"Head and Neck Cancer, Head and Neck Neoplasms","enrollment":21},{"nctId":"NCT05096663","phase":"PHASE2, PHASE3","title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-03-15","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":82},{"nctId":"NCT06765954","phase":"PHASE2","title":"Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-06-01","conditions":"High-risk Prostate Cancer","enrollment":20},{"nctId":"NCT06765902","phase":"PHASE2","title":"Immunotherapy Before and After Surgery","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-05-15","conditions":"High-risk Prostate Cancer","enrollment":20},{"nctId":"NCT04491955","phase":"PHASE2","title":"Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Small Bowel Cancers, Colorectal Cancers","enrollment":32},{"nctId":"NCT04505501","phase":"PHASE2","title":"Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thai Red Cross AIDS Research Centre","startDate":"2021-03-01","conditions":"HIV/AIDS","enrollment":14},{"nctId":"NCT04340596","phase":"PHASE1","title":"Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-21","conditions":"HIV Infection","enrollment":118},{"nctId":"NCT05981131","phase":"","title":"Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2023-08-17","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":6},{"nctId":"NCT01946789","phase":"PHASE1","title":"A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Altor BioScience","startDate":"2014-05","conditions":"Advanced Solid Tumors","enrollment":26},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT04142359","phase":"","title":"PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)","status":"TERMINATED","sponsor":"Altor BioScience","startDate":"2019-12-09","conditions":"Pharmacokinetics","enrollment":1},{"nctId":"NCT02099539","phase":"PHASE1","title":"QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Altor BioScience","startDate":"2014-10-06","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":19},{"nctId":"NCT04385849","phase":"PHASE1","title":"Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2020-07-22","conditions":"COVID-19","enrollment":1},{"nctId":"NCT03387085","phase":"PHASE1, PHASE2","title":"QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-03-19","conditions":"Triple Negative Breast Cancer","enrollment":9},{"nctId":"NCT03853317","phase":"PHASE2","title":"QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2020-02-19","conditions":"Merkel Cell Carcinoma","enrollment":9},{"nctId":"NCT03387111","phase":"PHASE1, PHASE2","title":"QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-01-09","conditions":"Squamous Cell Carcinoma","enrollment":4},{"nctId":"NCT02384954","phase":"PHASE1, PHASE2","title":"QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab","status":"TERMINATED","sponsor":"Altor BioScience","startDate":"2015-04-17","conditions":"Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma","enrollment":43},{"nctId":"NCT04927884","phase":"PHASE1, PHASE2","title":"A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2021-09-08","conditions":"Advanced Triple Negative Breast Cancer","enrollment":3},{"nctId":"NCT05769569","phase":"PHASE1","title":"Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2023-09-01","conditions":"HIV-1-infection","enrollment":""},{"nctId":"NCT02465957","phase":"PHASE2","title":"QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2015-09-24","conditions":"Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma","enrollment":7},{"nctId":"NCT05445882","phase":"PHASE2","title":"N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-01","conditions":"Castration Resistant Prostate Cancer","enrollment":""},{"nctId":"NCT04808908","phase":"PHASE1","title":"Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2021-04-01","conditions":"Hiv, HIV Infections, AIDS","enrollment":10},{"nctId":"NCT02989844","phase":"PHASE2","title":"Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-04-12","conditions":"Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":20},{"nctId":"NCT05007769","phase":"PHASE2","title":"Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2021-10-31","conditions":"Non-small Cell Lung Cancer, Non-small Cell Carcinoma, NSCLC","enrollment":""},{"nctId":"NCT03899480","phase":"PHASE1","title":"Adoptive Transfer of Haploidentical NK Cells and N-803","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2019-05-01","conditions":"Hiv, HIV Infections, Immune Deficiency","enrollment":9},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""},{"nctId":"NCT04144335","phase":"PHASE1, PHASE2","title":"N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2020-01-01","conditions":"Hiv, HIV/AIDS, HIV Infections","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CHILLS"},{"count":1,"reaction":"NAUSEA"},{"count":1,"reaction":"NEUTROPENIA"},{"count":1,"reaction":"PYREXIA"},{"count":1,"reaction":"TOXICITY TO VARIOUS AGENTS"}],"_approvalHistory":[],"publicationCount":345,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]), ALT-803","ALT-803","Anktiva","Nant-803","Formerly known as ALT-803"],"phase":"phase_3","status":"active","brandName":"N-803","genericName":"N-803","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"N-803 is a superagonist of the IL-15 receptor that expands and activates natural killer cells and CD8+ T cells to enhance anti-tumor immunity. Used for Metastatic melanoma (in combination with checkpoint inhibitors), Renal cell carcinoma, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":17,"withResults":11},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}